SALT LAKE CITY--(BW HealthWire)--July 23, 1999--
IOMED, Inc. (AMEX: IOX) today announced the introduction of the Phoresor(R) PM900 dose controller into the rehabilitative medicine market for the treatment of acute inflammatory conditions. The Phoresor PM900, which incorporates the Company's latest iontophoretic drug delivery technology, operates at the touch of a button to reduce set-up time and improve the efficiency of iontophoretic drug delivery treatments.
The unit is pre-programmed for a 40mA-minute dose with 2.0, 3.0 and 4.0mA current setting options. The current can be adjusted any time during the treatment and the treatment time is automatically adjusted. The Phoresor PM900 features include:
- Simple push-button controls - Pre-programmed 40mA-minute dose with variable current options for
straight-forward, easy operation - Compact and portable design - Integrated state-of-the-art electronics for safe drug delivery
The one-touch controls of the Phoresor PM900 offer clinicians quick set-up time and make it easier for patients to adjust the current based on their comfort level. In addition, the Phoresor PM900 is compatible with both IOGEL(TM) and TransQ(R) drug delivery electrodes. IOMED's proprietary electrodes stabilize the pH of the drug without using chemical buffers, and offer conformability and conductivity with the skin surface using a patented GelSponge(TM) element.
"The introduction of the Phoresor PM900 dose controller is another step in IOMED's continued commitment to offer the most advanced iontophoretic drug delivery technology available," said Robert J. Lollini, vice president, finance and chief financial officer. "By providing improved convenience and efficiency for both clinicians and patients, the Phoresor PM900 should further enhance the Company's competitive position and support continued growth in product sales."
Iontophoresis is a non-invasive method of transporting water-soluble ionic drugs into and through the skin using mild electric current. Treatable conditions include acute local inflammatory conditions, such as carpal tunnel syndrome, lateral and medial epicondylitis, plantar fasciitis and other musculoskeletal inflammatory conditions. Iontophoresis is also used to induce rapid, local dermal anesthesia using IOMED's Iontocaine(R) (lidocaine HCI 2% with epinephrine 1:100,000 Topical Solution).
IOMED, Inc. is a leader in the research, development and manufacture of iontophoretic drug delivery systems, which are marketed to healthcare providers worldwide. Iontophoretic drug delivery involves the transport of water-soluble ionic drugs into and through the skin using a mild electrical current. IOMED also conducts advanced research for local and systemic delivery of ionic pharmaceutical compounds to treat various medical conditions.
The statements contained in this news release that are not purely historical are forward-looking statements, as defined in section 21E of the Securities and Exchange Act of 1934, and include IOMED's beliefs, expectations or intentions regarding its future operations and financial condition. All forward-looking statements included in this news release are made as of the date hereof and are based upon information available to IOMED as of such date. IOMED assumes no obligation to update any forward-looking statement. It is important to note that actual outcomes could differ materially from those in such forward-looking statements. Readers should also refer to the risk factors and other disclosures set forth in IOMED's filings with the Securities and Exchange Commission on Forms S-1 and 10-K.
COPYRIGHT 1999 Business Wire
COPYRIGHT 2000 Gale Group